Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Glioblastoma with novel EGFR mutations (T790M and exon 20 insertion) yet unresponsive to osimertinib: A case report.

Genes, chromosomes & cancer - 1 Jul 2023

Boongird Atthaporn, Lekcharoensombat Nopphon, Jinawath Artit, Theparee Talent, Jittapiromsak Nutchawan, Shuangshoti Shanop, Thorner Paul Scott, Teerapakpinyo Chinachote

Abstract excerpt

Glioblastoma (GBM) is a high-grade adult-type IDH-wildtype diffuse glioma, commonly harboring epidermal growth factor receptor (EGFR) amplification. Here, we describe a case of a 49-year-old man with a GBM harboring a TERT promoter mutation. Despite surgical and chemoradiation therapy, the tumor recurred. At that time, comprehensive genomic profiling by next-generation sequencing identified two rare mutations in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ErbB Receptors
Share to Glioblastoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Glioma Diagnosis and Treatment

Share to Lung Neoplasms

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 36994936
DOI: 10.1002/gcc.23143

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Glioblastoma with novel EGFR mutations (T790M and exon 20 insertion) yet unresponsive to osimertinib: A case report.PMID 36994936Read ↗

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma.Semantic proximity Read ↗

The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target?Semantic proximity Read ↗

Telomerase as a therapeutic target in glioblastoma.Semantic proximity Read ↗

A case of glioblastoma harboring non-amplified epidermal growth factor receptor variant III: Critical molecular detection using RNA-based panel analysis.Semantic proximity Read ↗

Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.Semantic proximity Read ↗

Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation.Semantic proximity Read ↗

Efficacy of Osimertinib Plus Bevacizumab In Glioblastoma Patients With Simultaneous EGFR Amplification And EGFRvIII MutationSemantic proximity Read ↗

A promising preclinical model for TERT promoter mutation in glioblastoma.Semantic proximity Read ↗

Dual TERT Promoter Mutations in Glioblastoma, IDH-Wildtype: A Case Report with Preclinical InvestigationsSemantic proximity Read ↗

Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain TumorSemantic proximity Read ↗

Next generation sequencing and molecular imaging identify EGFR mutation and amplification in a glioblastoma multiforme patient treated with an EGFR inhibitor: a case report.Semantic proximity Read ↗

Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.